Literature DB >> 19327830

Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.

Maryalice Stetler-Stevenson.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19327830      PMCID： PMC2683904          DOI： 10.1016/j.leukres.2009.02.029

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  9 in total

Review 1.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Authors:  Peter Valent; Hans-Peter Horny; John M Bennett; Christa Fonatsch; Ulrich Germing; Peter Greenberg; Torsten Haferlach; Detlef Haase; Hans-Jochen Kolb; Otto Krieger; Michael Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Michael Pfeilstöcker; Björn Rüter; Wolfgang R Sperr; Reinhard Stauder; Denise A Wells
Journal:  Leuk Res       Date:  2007-01-25       Impact factor: 3.156

2.  Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia.

Authors:  Steven J Kussick; Jonathan R Fromm; Anthony Rossini; Ying Li; Anthony Chang; Thomas H Norwood; Brent L Wood
Journal:  Am J Clin Pathol       Date:  2005-08       Impact factor: 2.493

3.  Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

Authors:  M Stetler-Stevenson; D C Arthur; N Jabbour; X Y Xie; J Molldrem; A J Barrett; D Venzon; M E Rick
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

4.  Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common.

Authors:  Samuel J Pirruccello; Ken H Young; Patricia Aoun
Journal:  Am J Clin Pathol       Date:  2006-06       Impact factor: 2.493

5.  Immunophenotypic clustering of myelodysplastic syndromes.

Authors:  Marc Maynadié; Françoise Picard; Bernard Husson; Bernard Chatelain; Yvan Cornet; Geneviève Le Roux; Lydia Campos; Alex Dromelet; Pascalle Lepelley; Hélène Jouault; Michèle Imbert; Michelle Rosenwadj; Véronique Vergé; Philippe Bissières; Martine Raphaël; Marie Christine Béné; Jean Feuillard
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study.

Authors:  Francoise Truong; Brian R Smith; Dariusz Stachurski; Jan Cerny; L Jeffery Medeiros; Bruce A Woda; Sa A Wang
Journal:  Leuk Res       Date:  2009-02-18       Impact factor: 3.156

7.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

Authors:  Denise A Wells; Martin Benesch; Michael R Loken; Carlos Vallejo; David Myerson; Wendy M Leisenring; H Joachim Deeg
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

8.  Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

Authors:  Arjan A van de Loosdrecht; Theresia M Westers; August H Westra; Angelika M Dräger; Vincent H J van der Velden; Gert J Ossenkoppele
Journal:  Blood       Date:  2007-10-30       Impact factor: 22.113

9.  Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities.

Authors:  Jose Luis Arroyo; Ma Eugenia Fernández; Jesús Maria Hernández; Alberto Orfao; Jesús Fernando San Miguel; Maria Consuelo del Cañizo
Journal:  Hematol J       Date:  2004
  9 in total
  2 in total

1.  Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data.

Authors:  Yu Qian; Chungwen Wei; F Eun-Hyung Lee; John Campbell; Jessica Halliley; Jamie A Lee; Jennifer Cai; Y Megan Kong; Eva Sadat; Elizabeth Thomson; Patrick Dunn; Adam C Seegmiller; Nitin J Karandikar; Christopher M Tipton; Tim Mosmann; Iñaki Sanz; Richard H Scheuermann
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

2.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.